The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > Physiogenex will be at the AASLD Liver Meeting 2017

News detail

Return to all news & events

10/09/2017 Physiogenex will be at the AASLD Liver Meeting 2017

Physiogenex will be attending the AASLD Liver Meeting 2017 in Washington DC, October 20th-24th, 2017.

If you wish to know more about our preclinical NASH models to optimize your preclinical drug development program,

please contact us to set-up an appointment with Dr. François Briand, Director of Research and Business Development during the Liver meeting.

We look forward seeing you in Washington DC!

About Physiogenex

Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.

Please visit our website for more information